Monsanto v. Durnell: The Supreme Court Preemption Ruling and What Survives for Your Roundup Cancer Case
You just heard the news. The Supreme Court ruled against people who sued over Roundup. You have non-Hodgkin’s lymphoma. You used Roundup for years — on the farm, in the yard, on the job — and you believed the company when it said the product was safe. Now a 7-2 decision from the highest court in the country feels like it just locked the courthouse door in your face.
Take a breath. The door is narrower than it was last month. It is not closed.
The decision in Monsanto v. Durnell does eliminate many failure-to-warn claims — the theory that Monsanto should have put a cancer warning on the Roundup label and did not. But the Court did something the headlines missed: it left open entire categories of claims that do not depend on labeling at all. Design defect claims — that Roundup is unreasonably dangerous by its very formulation — may survive. Fraud claims — that Monsanto manipulated the science behind its safety classification — may survive. And the retraction of a decades-old study that Monsanto secretly helped shape has handed plaintiffs the strongest fraud evidence this litigation has ever seen.
We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic tort and product liability cases across the country. This page is our senior trial team’s analysis of what Durnell actually did, what it did not do, and what it means for someone diagnosed with non-Hodgkin’s lymphoma after years of glyphosate exposure. We wrote it because the single most dangerous thing right now is a plaintiff who gives up based on a headline without learning what survived.
The Direct Answer: Is Your Roundup Case Still Alive?
Yes — if the right legal theory is built around the right evidence. The Durnell ruling preempts state-law failure-to-warn claims that would require Monsanto to add warnings beyond what the EPA approved on the Roundup label. If your entire case was “they should have warned me on the label,” that specific path is now significantly harder.
But if your case is built on the theory that Roundup is dangerous by design — that the product formulation itself is unreasonably hazardous, regardless of what the label says — that claim operates on a different legal track that Durnell did not close. And if your case includes a fraud theory — that Monsanto shaped the safety science without disclosing its involvement, and that the EPA’s approval was built on compromised data — the retraction of the 2000 study gives you evidence that did not exist when most prior Roundup cases were tried.
The honest assessment: the path is narrower, the legal fight is harder, and the case must be built with more precision than before. But the courthouse door is open for claims constructed on the surviving theories.
What the Supreme Court Actually Held in Monsanto v. Durnell
The Federal Insecticide, Fungicide, and Rodenticide Act — FIFRA — is the federal law that governs how pesticides are registered, labeled, sold, and used in the United States. Under FIFRA, the EPA reviews pesticide products and approves the labels that appear on them. The EPA classified glyphosate — Roundup’s active ingredient — as “not likely to be carcinogenic when used as directed.” That classification has been the foundation of Monsanto’s defense for years.
In Durnell, the Supreme Court held that FIFRA preempts many state-law claims against pesticide manufacturers whose labels have been approved by the EPA. The majority opinion reasoned that because Congress vested the EPA with authority over pesticide labeling, states cannot use their own tort law to require warnings beyond what the federal agency approved.
Because Congress has given the EPA authority over pesticide labeling, states cannot use tort law to require more.
That is the core of the ruling. It creates a federal floor: if the EPA approved a label, a state jury generally cannot conclude that the label was inadequate under state law and hold the manufacturer liable for not adding more warnings.
The decision was 7-2. Justice Kavanaugh wrote the majority opinion. The ruling applies nationwide — it displaces state failure-to-warn remedies in every jurisdiction, though the exact scope of what counts as “many” versus all claims will be defined by lower courts as they interpret the boundary in the months and years ahead.
Which Claims Are Preempted — and Which Survive
This is the section that decides whether your case has a future. The distinction is not subtle, and the defense will try to blur it.
Preempted by Durnell — significantly limited or barred:
Failure-to-warn claims — the theory that Monsanto failed to warn users about cancer risks from glyphosate exposure. These claims are now significantly limited for cases requiring warnings beyond the EPA-approved label. Claims tied to labels approved before the EPA’s current safety review face the strongest preemption barrier. If your case depends on arguing that the label should have carried a cancer warning and the EPA did not require one, Durnell stands in the way.
Potentially surviving Durnell — the post-Durnell litigation tracks:
Design defect claims — the theory that Roundup is unreasonably dangerous by design, independent of any labeling issue. This is not a claim about what the label said or did not say. It is a claim about the product formulation itself — that glyphosate, as designed and formulated, creates an unreasonable risk of cancer that a reasonable alternative design could have reduced or eliminated. Because this theory is not premised on requiring additional label warnings, it operates outside the preemption analysis the Court applied in Durnell. Lower courts will define the exact boundary, but the theory is structurally distinct from the failure-to-warn claims the Court struck down.
Fraudulent misrepresentation and fraud on the agency — claims based on the retracted 2000 study and Monsanto’s undisclosed role in shaping scientific literature submitted to regulators. This theory does not demand additional label warnings. It challenges the integrity of the regulatory process itself — arguing that the EPA’s approval was built on compromised data. If the agency’s decision was based on science that the manufacturer secretly manipulated, the preemption defense loses its moral and logical foundation. The manufacturer cannot simultaneously say “the EPA approved our label, so we are immune” and “we secretly shaped the science that led the EPA to approve our label.” The fraud theory attacks the legitimacy of the very approval the manufacturer is using as a shield.
Negligent testing and research manipulation — claims that Monsanto knowingly produced and promoted compromised science to maintain regulatory approval. This is strengthened by the journal’s retraction finding — the documented evidence that Monsanto scientists played an undisclosed role in developing and shaping the study that regulators and the company itself relied on for decades. Internal document discovery from prior multidistrict litigation proceedings provides an established evidentiary foundation for these claims.
The killer takeaway here is what the generalist misses: the fraud theory does not just survive Durnell — it undermines Durnell. If the regulatory approval was obtained through deception, the preemption defense that rests on that approval is built on sand. A lawyer who files only a failure-to-warn complaint after Durnell may get dismissed. A lawyer who pleads design defect and fraud, supported by the retracted study evidence, is building on ground the Supreme Court did not touch.
The Retracted 2000 Study: How Monsanto’s Undisclosed Role Creates New Fraud Claims
For decades, a scientific paper published in 2000 was cited by regulators and by Bayer as evidence that glyphosate poses no meaningful human health risks. The study was widely relied upon. It shaped the regulatory record. It was part of the foundation upon which the EPA concluded that glyphosate was “not likely to be carcinogenic when used as directed.”
Then the journal retracted it.
The retraction came after the journal found that Monsanto scientists had played an undisclosed role in developing and shaping the research. This was not a minor editorial oversight. It was a fundamental breach of scientific transparency: the people with the most to lose from a cancer finding had helped craft the study that found no cancer risk, and they did so without disclosure.
For the litigation, this retraction is transformative. It provides documented evidence — not allegation, not inference, but the journal’s own finding — that the scientific record supporting glyphosate’s safety classification was compromised by undisclosed manufacturer involvement. This evidence did not exist when the majority of the 65,000 pending Roundup lawsuits were filed and litigated. It opens a legal avenue that was not available to most prior plaintiffs.
The fraud-on-the-agency theory works like this: Monsanto submitted or promoted scientific literature to the EPA. That literature included the 2000 study. The study concluded glyphosate was safe. The EPA relied on that body of literature in classifying glyphosate as not likely to be carcinogenic. The EPA then approved the Roundup label based on that classification. Monsanto now argues that the EPA-approved label preempts state-law claims. But the study that helped form the basis of the EPA’s decision was secretly shaped by Monsanto’s own scientists. The regulatory approval — the very thing Monsanto is using as a preemption shield — may have been built on compromised science.
This theory may bypass FIFRA preemption because it does not demand additional label warnings. It challenges the integrity of the process that produced the label approval in the first place. It is a fundamentally different legal argument from “you should have warned us” — it says “you corrupted the process that decided whether a warning was needed.”
The communications between Monsanto personnel and the authors of the 2000 study are not yet fully public. The retraction is public record, but the underlying editorial correspondence — the emails, the drafts, the revision histories that show exactly how Monsanto scientists shaped the paper — require targeted discovery. This is perishable evidence held by the defendant and potentially by third parties. It must be sought through formal discovery channels, and the litigation hold that preserves it should attach the moment a case is opened.
Design Defect: The Primary Post-Durnell Litigation Track
After Durnell, the design defect claim becomes the primary liability track for Roundup plaintiffs. Here is how it works and why it survives.
A design defect claim says the product is unreasonably dangerous because of how it was formulated — not because of what the label said or did not say. The question is not “should Monsanto have warned about cancer?” The question is “is Roundup, as designed and formulated, unreasonably dangerous, and was there a reasonable alternative design that would have reduced the risk?”
This theory is structurally distinct from a failure-to-warn claim. It does not ask the jury to require a different label. It asks the jury to evaluate the product itself — the chemical formulation, the concentration, the delivery mechanism, the foreseeable uses — and determine whether the design creates an unreasonable risk. The preemption analysis in Durnell turned on the EPA’s authority over labeling. A design defect claim does not implicate labeling authority. It implicates product design.
To build a design defect case post-Durnell, the evidence focuses on:
Monsanto’s internal knowledge of glyphosate’s carcinogenic potential — internal communications, research memos, and scientific assessments that show what the company knew about cancer risk and when. The prior MDL proceedings produced extensive document discoveries. Internal documents showing that Monsanto scientists or executives were aware of studies suggesting carcinogenic risk — or that they worked to discredit such studies — are the foundation of both the design defect theory and the punitive damages case.
The existence of reasonable alternative designs or formulations — evidence that Roundup could have been formulated differently to reduce cancer risk, or that alternative herbicidal products existed with lower carcinogenic potential, or that the concentration or delivery method could have been modified. This is where a product liability expert becomes essential — a formulation chemist or toxicologist who can testify about what a safer design would have looked like and whether it was technically and economically feasible.
The foreseeable use patterns — Roundup is the most widely used herbicide in the United States. Millions of people — farmers, landscapers, groundskeepers, homeowners — have used it repeatedly over years or decades. The exposure is not a one-time accident. It is chronic, repeated, and foreseeable. A design defect theory argues that the product was designed for mass repeated use, and that the design did not adequately account for the cumulative cancer risk from that use pattern.
The consumer expectations — people who bought Roundup were told it was safe. They were not told it was probably carcinogenic. The IARC — the International Agency for Research on Cancer, the World Health Organization’s cancer arm — classified glyphosate as “probably carcinogenic to humans” in 2015. The EPA’s position has been the opposite. This discrepancy is itself evidence in a design defect case: if the world’s leading cancer authority says probably carcinogenic, a jury can evaluate whether a product designed for mass repeated exposure is unreasonably dangerous when the manufacturer dismisses that classification.
The EPA’s Ongoing Safety Review: A Dynamic Legal Landscape
The legal landscape for Roundup claims is not static. It is actively shifting in ways that could reopen litigation avenues.
The EPA is currently conducting a safety review of glyphosate under heightened political scrutiny — including pressure from allies of the Secretary of Health and Human Services. This review includes reevaluating the evidence supporting the product’s approved labeling. If the agency revises its carcinogenicity classification — if it moves from “not likely to be carcinogenic” to some form of recognized cancer risk — the preemption analysis could shift for claims arising after any label change.
Here is why this matters: Durnell’s preemption ruling rests on the EPA’s current classification. If the classification changes, the foundation of the preemption defense changes. A plaintiff whose exposure occurs after a revised EPA classification — and after a corresponding label change — may face a completely different preemption landscape than a plaintiff whose exposure occurred under the current classification.
Even for past exposures, the ongoing review is relevant. If the EPA revisits the evidence and finds it was compromised — particularly in light of the retracted 2000 study — that reconsideration strengthens the fraud-on-the-agency theory. It shows that the regulatory process is not final, that the science is not settled, and that the foundation of the preemption shield is not as solid as the manufacturer claims.
What this means for you: the window for filing may be open now, but the legal landscape could shift in either direction. If the EPA strengthens its classification, more claims could become viable. If the Durnell precedent is extended by lower courts, fewer claims might survive. Acting now — while the surviving theories are established and the retracted study evidence is available — may be the strongest position.
Non-Hodgkin’s Lymphoma: The Injury and What It Costs
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system. It begins in lymphocytes — white blood cells that are part of the body’s immune defense. NHL is not a single disease. It is a group of blood cancers that includes many subtypes, ranging from indolent (slow-growing) forms that may smolder for years to aggressive forms that require immediate intensive treatment.
The mechanism from glyphosate to NHL: The proposed causal pathway is that chronic glyphosate exposure causes cellular damage — through oxidative stress, DNA damage, and immune system disruption — that leads to abnormal lymphocyte proliferation and, eventually, malignancy. The IARC’s 2015 classification of glyphosate as “probably carcinogenic to humans” (Group 2A) was based on limited evidence of cancer in humans and sufficient evidence in experimental animals. The EPA’s contrary position — “not likely to be carcinogenic when used as directed” — is the basis of the preemption defense. The conflict between these two assessments is itself part of the case.
Diagnosis and treatment: NHL is diagnosed through lymph node biopsy, blood tests, bone marrow examination, and imaging (CT, PET). Treatment depends on the subtype and stage but commonly includes:
- Chemotherapy regimens — many B-cell NHLs are treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or similar multi-drug combinations
- Radiation therapy — targeted to affected lymph node regions
- Immunotherapy — monoclonal antibodies like rituximab that target specific cancer cell markers
- Stem cell transplants — for advanced, relapsed, or refractory cases, autologous (own cells) or allogeneic (donor cells) transplants
- CAR-T cell therapy — an advanced immunotherapy for certain relapsed or refractory cases
The cost: The financial burden of NHL is staggering. Chemotherapy regimens run tens of thousands of dollars per cycle. A stem cell transplant can cost hundreds of thousands. Immunotherapy drugs are among the most expensive medications in oncology. Add lost wages — during treatment and recovery, which can span months to years — and the economic impact compounds rapidly.
The human toll: Beyond the medical bills, NHL patients live with the psychological weight of a cancer diagnosis — the fear of relapse, the exhaustion of treatment, the changes in family roles, the loss of the life they had planned. A plaintiff who was told Roundup was safe and then developed a blood cancer carries a specific kind of anger — the anger of someone who followed the rules, trusted the label, and was betrayed by the science behind it.
The proof problem the defense exploits: NHL has many causes. It is one of the most common blood cancers in the United States, and its etiology is not fully understood. The defense will argue that your NHL came from something else — age, genetics, other chemical exposures, immune conditions, or pure chance. Specific causation — proving that YOUR NHL came from glyphosate and not from another source — is the hardest part of the case. It requires expert testimony in hematologic oncology and occupational toxicology, dose reconstruction showing the amount and duration of your glyphosate exposure, and a differential diagnosis that rules out other plausible causes.
For families who have lost someone to NHL, the damages include wrongful death and survival claims. Survival damages cover the victim’s pain, suffering, and medical costs between diagnosis and death. Wrongful death damages compensate the family for lost financial support, lost companionship, and the life the deceased would have lived. The specific recovery rules and beneficiary classes vary by state — our wrongful death practice handles these claims.
Monsanto and Bayer: The Corporate Structure and the Three-Part Strategy
Monsanto Company is the manufacturer of Roundup. Bayer AG — the German pharmaceutical and agricultural chemical giant — acquired Monsanto in 2018. The acquisition was a deliberate corporate strategy: Bayer bought Monsanto’s product portfolio, its pipeline, and its legal liability. Bayer is the deep-pocket defendant, with global pharmaceutical and agricultural chemical revenue that dwarfs most national corporations.
Bayer developed what the reporting describes as a three-part strategy to minimize its liability:
Part one — scientific publication: Bayer published scientific literature defending glyphosate’s safety. The retracted 2000 study is now the most visible example of this strategy — a study that concluded glyphosate posed no meaningful health risks, shaped in undisclosed ways by Monsanto scientists, cited for decades by regulators and the company as proof of safety. This is the strategy that is now backfiring. The retraction is the crack in the foundation.
Part two — legislative lobbying: Bayer lobbied state legislatures to immunize pesticide manufacturers from failure-to-warn lawsuits. It pushed bills providing that if the EPA approves a warning label, pesticide manufacturers cannot be sued for failing to provide additional warnings. In most states, these proposals stalled amid bipartisan concerns about eliminating state tort remedies. At the federal level, a bipartisan coalition stripped pesticide liability protections from a must-pass agriculture bill. The legislative strategy largely failed — the democratic process did not give Bayer the immunity it sought.
Part three — judicial preemption: Bayer argued in court that federal law bars many of these claims altogether. This is the strategy that succeeded at the Supreme Court. After failing to convince legislatures to limit liability through the political process, the company turned to the courts — and won.
The narrative matters for a jury. Bayer tried to win through science and failed when the study was retracted. Bayer tried to win through legislation and failed when lawmakers refused. Bayer turned to the Supreme Court and won. That sequence — losing in the lab, losing in the legislature, winning in the courtroom — is the story that undermines the legitimacy of the preemption defense before a lay jury on surviving claims. It resonates across political lines. It is not a legal argument. It is a story about power, and jurors understand it.
The corporate structure also matters for who you sue. Monsanto Company is the manufacturer — the entity that designed Roundup, tested it, labeled it, and marketed it. Bayer AG is the parent — the entity that acquired Monsanto’s liability along with its assets, that directed the three-part strategy, and that has the financial resources to pay substantial verdicts. Naming the right entities — the operating subsidiary and the parent corporation — is foundational. The corporate-structure analyst’s job is to identify every entity in the chain that designed, manufactured, marketed, profited from, or controlled the product that caused the harm.
The Evidence Clock: What Exists, Who Holds It, How Fast It Disappears
Every piece of evidence in a Roundup cancer case is on a clock. Some of it is already preserved in prior litigation. Some of it is degrading right now. Some of it is in the hands of a defendant that has every incentive to let it disappear.
Monsanto/Bayer internal communications regarding glyphosate carcinogenicity research — These documents prove actual knowledge of cancer risks and deliberate concealment from regulators and the public. They are central to fraud and punitive damages theories. The richest source is the existing document productions from prior multidistrict litigation proceedings — millions of pages of internal emails, memos, and research files that were produced under discovery orders and are accessible through coordination with prior MDL counsel. New plaintiffs must access these existing productions rather than starting from scratch. These documents are the heart of the case.
The retracted 2000 study and related authorship and editorial correspondence — The retraction itself is public record. But the underlying communications between Monsanto personnel and the study’s authors — the emails, the draft revisions, the editorial decisions that show how Monsanto shaped the paper — require targeted discovery. These are held by the defendant and potentially by the journal and the authors. They are perishable. The litigation hold that preserves them must attach the moment a case is filed.
EPA registration files, label approval history, and safety review records — These establish what the agency approved, when it approved it, and on what evidentiary basis. They determine the preemption scope for each plaintiff’s exposure period. Agency records are permanent, but the ongoing safety review may produce conflicting classifications that strengthen the plaintiff’s position. These are obtainable through public records requests and formal discovery.
Your medical records, pathology reports, and exposure history documentation — These prove specific causation. Your medical records — the biopsy, the pathology report, the treatment history, the imaging — must be obtained before provider destruction schedules run. Exposure history is the most perishable evidence of all. Purchase receipts for Roundup, employment records showing agricultural or landscaping use, witness statements from coworkers or family members who can describe your use patterns — all of this degrades with time. People forget. Employers go out of business. Receipts are thrown away. The exposure history that links your cancer to glyphosate is the evidence most likely to be lost to delay.
Prior MDL expert depositions and trial testimony — The consolidated Roundup litigation produced extensive expert witness depositions and trial testimony. These are established evidentiary records that provide a foundation without duplicative discovery costs. Coordinating with prior MDL counsel to access these productions is a strategic move that saves time and resources.
The preservation letter goes out the day you call. That is not a marketing line — it is the single most important step in the first 72 hours. The letter formally demands that Monsanto/Bayer preserve all internal communications, all scientific research records, all regulatory submissions, and all documents related to the retracted 2000 study. Once the letter is on file, the defendant’s destruction of relevant documents becomes spoliation — a separate wrong that can trigger adverse inference instructions (the jury may assume the lost evidence was as bad as the plaintiff says) and sanctions.
What Your Case Is Worth After Durnell
The honest answer starts with what changed and what did not.
Before Durnell: Individual Roundup verdicts reached tens of millions of dollars, including punitive damages. Aggregate verdicts across the litigation were in the billions. The failure-to-warn theory was the primary liability track, and it produced substantial results.
After Durnell: The failure-to-warn track is significantly narrowed. Case values on that specific theory are deflated. But design defect and fraud-based theories — strengthened by the retracted 2000 study — may still support substantial compensatory and punitive awards, particularly against Bayer’s deep pockets.
The case value range post-Durnell:
Low end: approximately $750,000 — for a plaintiff with moderate exposure, a treatable NHL subtype, strong treatment response, and a case built primarily on surviving theories with limited punitive evidence.
High end: $15,000,000 or more — for a plaintiff with extensive chronic exposure, an aggressive NHL subtype requiring stem cell transplant, significant pain and suffering, and strong fraud evidence supporting punitive damages. Bayer’s global exposure and resources mean the ceiling on a strong case is still very high.
The factors that drive value:
- Venue — some jurisdictions are more plaintiff-friendly than others; state tort reform provisions, damage caps, and comparative fault rules vary
- Exposure duration and intensity — a farmworker who mixed and sprayed Roundup daily for 20 years has a stronger specific causation case than a homeowner who used it occasionally
- Cancer subtype and treatment response — an aggressive NHL requiring stem cell transplant carries higher medical costs, greater pain and suffering, and a more compelling damages narrative
- Which legal theories survive preemption analysis — design defect and fraud theories that survive early motion practice carry the case to a jury; theories that get dismissed never reach a verdict
- Punitive damages evidence — the retracted study and internal documents showing knowledge and concealment create a strong punitive damages foundation. Some states cap punitive damages; some do not. The specific cap rules must be confirmed for the applicable jurisdiction.
Economic damages — the part the defense cannot cap in most states — include past and future medical costs, lost wages, and lost earning capacity. A life-care planner builds the cost stream for ongoing treatment, monitoring, and potential relapse care. A forensic economist reduces it to present value. These are real dollars, built from real medical records and real employment data, and they are the floor of the case.
Non-economic damages — pain, suffering, emotional distress, loss of quality of life — are the human losses no receipt can measure. These are the damages the defense tries to minimize and that caps sometimes restrict. But they are also the damages a jury weighs heaviest when the evidence shows a company knew its product might cause cancer and shaped the science to hide it.
For a deeper discussion of how case value is built, Ralph Manginello has recorded a video on what a personal injury case is worth — the principles transfer directly to toxic tort valuation.
The Defense Playbook: What Bayer Will Try — and How Each Play Is Countered
After Durnell, the defense has new ammunition. Here are the plays you should expect — and the counter to each.
Play 1: “The Supreme Court already decided this — your case is preempted.”
This is the first line of every defense motion after Durnell. The company will argue that the Supreme Court closed the door on all Roundup claims and that your case is no different from the ones the Court struck down.
The counter: Durnell preempted failure-to-warn claims that require additional label warnings. It did not address design defect claims. It did not address fraud claims. It did not address negligent testing claims. The Supreme Court said “many” state-law claims are preempted — not all. The complaint must be pleaded to survive: design defect as the primary track, fraud as the secondary track, with the retracted study as the anchor evidence. A complaint that leads with failure-to-warn may be dismissed. A complaint that leads with design defect and fraud is built on ground the Court did not touch.
Play 2: “The EPA said glyphosate is safe — your cancer came from something else.”
The defense will point to the EPA’s classification — “not likely to be carcinogenic when used as directed” — and argue that the plaintiff cannot prove general causation, let alone specific causation.
The counter: The IARC — the world’s leading cancer authority — classified glyphosate as “probably carcinogenic to humans.” The defense has to explain why it relies on the EPA’s assessment while ignoring the IARC’s contradictory classification. More importantly, the fraud theory attacks the foundation of the EPA’s assessment: if the 2000 study that helped form the EPA’s conclusion was secretly shaped by Monsanto scientists, the EPA’s classification may rest on compromised science. The defense cannot simultaneously defend the EPA’s classification and defend the integrity of the study the EPA relied on when that study has been retracted for undisclosed manufacturer involvement.
Play 3: “Non-Hodgkin’s lymphoma has many causes — you cannot prove Roundup caused yours.”
This is the specific causation attack. NHL is a common cancer with multiple known and unknown risk factors. The defense will argue that the plaintiff’s cancer could have come from age, genetics, other chemical exposures, immune conditions, or random chance.
The counter: Specific causation is proven through expert testimony in hematologic oncology and occupational toxicology, dose reconstruction showing the amount and duration of glyphosate exposure, temporal relationship between exposure and diagnosis, and differential diagnosis that evaluates and rules out other plausible causes. The plaintiff’s exposure history — years of repeated Roundup use, the mixing and spraying patterns, the absorption routes — is the foundation. The stronger the exposure evidence, the stronger the specific causation case.
Play 4: Delay and complexity — the slow-walk tactic.
The defense will use the complexity of the post-Durnell legal landscape to slow the case. More motions. More briefing. More discovery disputes. The goal is to exhaust the plaintiff financially and emotionally — to make the fight so long and so expensive that the plaintiff accepts a fraction of the case’s true value.
The counter: This is where the firm’s experience and resources matter. A firm that handles mass tort litigation knows the delay tactics and has the infrastructure to push through them. The contingency fee structure means the plaintiff does not pay hourly — the firm bears the cost of the fight. Ralph Manginello has spent 27-plus years in courtrooms, including federal court. Lupe Peña spent years inside a national insurance-defense firm before joining this side of the table — he knows how the other side values claims, how adjusters set reserves, and how delay is used as leverage.
Play 5: “The study retraction does not prove fraud — it proves an editorial oversight.”
The defense will minimize the retracted study, arguing that undisclosed manufacturer involvement in a scientific paper is a common practice, not fraud, and that the retraction does not prove the study’s conclusions were wrong.
The counter: The journal retracted the paper because it found Monsanto scientists played an undisclosed role in developing and shaping it. That is the journal’s own finding — not the plaintiff’s allegation. The retraction speaks for itself. Whether the conclusions were right or wrong is beside the point: the integrity of the process was compromised, and the regulatory decision that relied on that process is therefore questionable. The jury does not need to decide whether glyphosate causes cancer based on one study. The jury needs to decide whether a company that secretly shaped the science behind its own safety classification can then use that classification as a shield against liability. That is a question about corporate integrity, and jurors across political lines answer it the same way.
How a Surviving Case Is Built: The Proof Story
Here is how a post-Durnell Roundup case is actually built — from the first call to the courtroom.
Week one: the preservation letter. The day you call, a formal preservation demand goes out to Monsanto/Bayer. It names every category of evidence: internal communications about glyphosate carcinogenicity, all documents related to the retracted 2000 study, all regulatory submissions, all internal research files, all emails and memos referencing IARC’s classification, all documents showing the company’s response to the retraction. Once that letter is on file, the destruction of any named document becomes spoliation.
Weeks two through four: the evidence inventory. Your medical records are pulled — the biopsy, the pathology report confirming NHL subtype, the treatment history, the imaging, the blood work. Your exposure history is documented — when you used Roundup, how often, for how many years, in what quantities, through what routes (mixing, spraying, skin contact, inhalation). Purchase records, employment records, coworker statements, family testimony. The existing MDL document productions are accessed through coordination with prior counsel — millions of pages of Monsanto internal documents that are already in the litigation record.
Months one through three: the expert engagement. Expert witnesses in hematologic oncology, occupational toxicology, epidemiology, and regulatory science are essential. The oncologist proves specific causation — linking your NHL to glyphosate through dose, timing, and differential diagnosis. The toxicologist proves the exposure pathway and the biological mechanism. The epidemiologist testifies about the population-level evidence — the IARC classification, the studies showing elevated NHL risk in glyphosate-exposed populations. The regulatory science expert testifies about the fraud — how the 2000 study shaped the regulatory record and what the retraction means for the integrity of the EPA’s classification.
Months three through six: the complaint and initial motion practice. The complaint is pleaded to survive Durnell — design defect as the primary theory, fraud and negligent testing as the secondary theories, with the retracted study as the anchor. The defense will file a motion to dismiss based on preemption. The response brief argues that Durnell addressed failure-to-warn, not design defect or fraud, and that the fraud theory attacks the integrity of the regulatory approval the defense is using as a shield. This motion practice is the first legal battle — if the complaint survives, the case proceeds to discovery.
Months six through eighteen: discovery and depositions. Written discovery, document production, and depositions. The Monsanto/Bayer witnesses — the scientists, the executives, the regulatory affairs personnel — are deposed under oath. The questions focus on what they knew about cancer risk, when they knew it, what they did about it, and what role they played in shaping the scientific literature. The retracted study is the centerpiece — who at Monsanto was involved, what did they do, who knew about it, and was it disclosed to the EPA?
The mediation leverage. Bayer’s global exposure across the remaining Roundup inventory is enormous. Even post-Durnell, the company faces thousands of surviving claims built on design defect and fraud theories, strengthened by the retracted study evidence. The inconsistency between the Court’s anti-agency jurisprudence and its reliance on EPA approval in Durnell is a narrative that undermines the legitimacy of the preemption defense. Mediation leverage remains substantial — the company may prefer to settle strong cases rather than face juries with fraud evidence and the story of a company that lost in the lab, lost in the legislature, and won in the courtroom.
What to Do Right Now: The First 72 Hours
1. Get your medical records together. Your pathology report — the document that confirmed your NHL diagnosis and identified the subtype — is the foundation of the medical side of the case. Your treatment records, imaging, and blood work are the evidence of what the cancer has cost you. Request copies from your oncologist and your treatment center. Medical providers operate on retention schedules — these records will not live forever.
2. Write down your Roundup exposure history. While memory is fresh, document every detail you can: when you first used Roundup, how often you used it, for how many years, in what quantities, for what purposes (agricultural, landscaping, residential), how you were exposed (mixing, spraying, skin contact, inhalation), and whether you used personal protective equipment. Include purchase records if you have them. Include employment records if your exposure was occupational. Include names of coworkers or family members who can corroborate your use patterns.
3. Do not sign anything from Monsanto, Bayer, or any insurance company. If you receive a communication from the company or its insurers — a settlement offer, a release, a request for a statement — do not sign it, do not respond to it, and do not discuss your case with anyone who contacts you on their behalf. Any document you sign may be designed to extinguish your rights.
4. Do not post about your case on social media. The defense monitors social media. Posts about your health, your activities, your emotional state, or your opinions about the litigation can be taken out of context and used to undermine your case.
5. Call a lawyer. The preservation letter goes out the day you call. The evidence that is degrading right now — your exposure history, the internal documents that the defendant controls, the editorial correspondence behind the retracted study — is the evidence that a formal preservation demand can freeze. Contact us for a free consultation. The call costs nothing. The information you receive may change how you proceed.
The Statute of Limitations: How Long You Have
For toxic tort claims like Roundup cancer cases, the deadline to file a lawsuit varies by state. Most states have a personal injury statute of limitations ranging from two to three years. But for diseases with long latency periods — like cancer that may develop years or decades after exposure — most states apply a discovery rule.
The discovery rule means the clock does not start on the date you were exposed to Roundup. It starts when you knew or should have known two things: (1) that you had non-Hodgkin’s lymphoma, and (2) that your NHL may have been caused by glyphosate exposure. For many plaintiffs, that clock may have started at diagnosis — or when they first learned of the possible connection between Roundup and cancer.
Some states also have statutes of repose — outer deadlines that can cut off a claim even before discovery. These vary widely by jurisdiction and can be shorter than the discovery-rule period would otherwise allow.
Wrongful death claims — for families who have lost someone to NHL — have their own deadlines, typically shorter than the personal injury SOL, running from the date of death rather than the date of diagnosis.
The specific deadline for your case depends on your state, your date of diagnosis, when you learned of the possible Roundup connection, and whether any tolling rules or repose statutes apply. This is not a question to answer from a general article. It is a question to answer with a lawyer who can confirm the controlling deadline for your jurisdiction. Do not wait — the deadline is real, and missing it ends the case regardless of how strong the evidence is.
Frequently Asked Questions
Is my Roundup lawsuit dead after the Supreme Court decision?
No — but the path is narrower. The Durnell decision preempts many failure-to-warn claims (the theory that Monsanto should have added a cancer warning to the label). It did not address design defect claims (that the product formulation itself is unreasonably dangerous), fraud claims (that Monsanto manipulated the safety science), or negligent testing claims. If your case is built on these surviving theories, it may proceed. The retracted 2000 study — which showed undisclosed Monsanto involvement in shaping the safety research — provides fraud evidence that did not exist when most prior cases were tried.
What is FIFRA preemption and why does it matter?
FIFRA is the federal law that governs pesticide registration and labeling. The EPA approves pesticide labels under FIFRA. In Durnell, the Supreme Court held that because Congress gave the EPA authority over pesticide labeling, state courts cannot use state tort law to require warnings beyond what the EPA approved. This means that if your entire case is “Monsanto should have warned me on the label,” the preemption ruling makes that case harder. But claims that do not depend on labeling — like design defect and fraud — operate on a different legal track.
Can I still sue if I was diagnosed with non-Hodgkin’s lymphoma after using Roundup?
Yes, if the right legal theory is built around the right evidence. Design defect claims (that Roundup is dangerous by formulation), fraud claims (that Monsanto shaped the safety science), and negligent testing claims may survive Durnell. The retracted 2000 study strengthens the fraud theory. Your exposure history and medical records are the foundation. The specific viability of your case depends on the strength of your exposure evidence, your cancer subtype, and which legal theories survive preemption analysis in your jurisdiction.
What is the retracted 2000 glyphosate study and why does it matter for my case?
A scientific paper published in 2000 concluded that glyphosate posed no meaningful human health risks. It was cited for decades by regulators and by Bayer as evidence of safety. The journal retracted the paper after finding that Monsanto scientists played an undisclosed role in developing and shaping it. This retraction is transformative evidence because it provides documented proof — the journal’s own finding — that the scientific record supporting glyphosate’s safety was compromised by undisclosed manufacturer involvement. This supports a fraud-on-the-agency theory that may bypass FIFRA preemption because it challenges the integrity of the regulatory process rather than demanding additional label warnings.
How long do I have to file a Roundup lawsuit?
The deadline varies by state. Most states have a 2-to-3-year personal injury statute of limitations, but most also apply a discovery rule for toxic tort claims — meaning the clock starts when you knew or should have known of your injury and its connection to glyphosate, not from the date of exposure. For many plaintiffs, that clock starts at diagnosis or when they first learned of the Roundup-cancer connection. Some states have statutes of repose that create outer deadlines. Wrongful death claims have separate, typically shorter deadlines. The specific deadline for your case must be confirmed for your jurisdiction — do not rely on a general time frame.
What is my Roundup case worth after Durnell?
Case values range widely depending on the strength of the surviving theories, the jurisdiction, the exposure evidence, and the cancer subtype. Post-Durnell, failure-to-warn claims face preemption and reduced value, but design defect and fraud theories — strengthened by the retracted study — may support substantial compensatory and punitive awards. Individual case value depends on venue, exposure duration and intensity, cancer stage and treatment response, and which legal theories survive preemption analysis. Bayer’s deep pockets and global exposure mean the ceiling on a strong case remains high.
What evidence do I need for a Roundup cancer case?
You need four categories of evidence: (1) your medical records — the pathology report confirming NHL, treatment history, imaging, and blood work; (2) your exposure history — when, how often, and for how long you used Roundup, documented through purchase records, employment records, and witness statements; (3) Monsanto/Bayer internal documents — available through prior MDL discovery productions, showing what the company knew about cancer risk and when; and (4) the retracted 2000 study and related correspondence — showing undisclosed manufacturer involvement in shaping the safety science. The preservation letter that freezes the defendant’s documents goes out the day you call a lawyer.
Did the EPA say Roundup is safe?
The EPA classified glyphosate as “not likely to be carcinogenic when used as directed.” That classification is the basis of Monsanto’s preemption defense. But the IARC — the International Agency for Research on Cancer, the World Health Organization’s cancer authority — classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015. These contradictory classifications are part of the case. And the EPA is currently conducting a renewed safety review that could revise its classification — particularly in light of the retracted 2000 study that contributed to the scientific record the EPA relied upon.
What if I signed something from Monsanto or Bayer?
Do not assume a release or settlement agreement is valid without having a lawyer review it. Depending on how it was obtained, what it covers, and the law of your jurisdiction, it may or may not bar your surviving claims. If you signed something — a release, a settlement, a participation in a claims program — bring it to the consultation. The specific language and the circumstances of signing determine whether it stands.
Why This Firm
Ralph Manginello has spent 27-plus years in courtrooms, including federal court. He was a journalist before he was a lawyer — he knows how to find the story in the documents, how to build the narrative that makes a jury understand not just what happened but why it matters. He handles cases that turn on corporate accountability — on proving that a company knew, concealed, and chose profit over safety. The Roundup litigation, post-Durnell, is exactly that kind of case. The surviving theories — design defect, fraud, negligent testing — are built on what the company knew and what it hid.
Lupe Peña spent years inside a national insurance-defense firm before joining this side of the table. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the other side values a toxic tort case, how they set reserves, how they use complexity and delay as leverage. He uses that knowledge for injured clients now. He is fluent in Spanish and conducts full consultations in Spanish without an interpreter — hablamos Español — because the agricultural workers and landscapers who have the heaviest Roundup exposure include many whose first language is not English.
We work on contingency. That means you pay nothing unless we win your case. The fee is 33.33% before trial and 40% if the case goes to trial. We do not get paid unless you recover. The consultation is free. How contingency fees work is a question Ralph has answered in detail — the short version is that the firm bears the cost of the fight, and the firm only earns a fee if the fight produces a recovery.
The call is free. The number is 1-888-ATTY-911 — 1-888-288-9911. We answer 24 hours a day, seven days a week. You will speak to a live person, not an answering service. The consultation is confidential. The information you receive is honest — if your case is not viable after Durnell, we will tell you. If it is viable, we will tell you how and why.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Nothing here creates an attorney-client relationship. The specific deadline for your case, the specific legal theories that survive in your jurisdiction, and the specific value of your claim must be confirmed in consultation with a lawyer licensed in your state.
If you or someone you love was diagnosed with non-Hodgkin’s lymphoma after years of Roundup exposure, the Supreme Court narrowed the road. It did not close it. The retracted study, the surviving theories, and the evidence of what Monsanto knew are still in play. The question is whether you act while they are.
Call 1-888-ATTY-911. The preservation letter goes out the day you do.
